<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>106(1)</volume><submitter>Kong Q</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Whether patients suffering liver oligometastases from pancreatic ductal adenocarcinoma (LOPDA) should undergo surgical treatment remains controversial.&lt;h4>Methods&lt;/h4>PubMed and Embase databases were systematically reviewed until 2023 June. Survival data were collected from the Kaplan-Meier curves. Safety and survival were evaluated using primary outcomes such as 1-year, 3-year, and 5-year survival rates, and 30-day mortality and morbidity. A subgroup meta-analysis was conducted to compare survival rates post-synchronous resection and resection post-neoadjuvant chemotherapy in LOPDA.&lt;h4>Results&lt;/h4>Our analysis of 15 studies involving 1,818 patients (surgical group, 648 and nonsurgical group, 1,170) indicates that radical hepatectomy for LOPDA notably improved 1-year (odds </pubmed_abstract><journal>Annals of surgical treatment and research</journal><pagination>51-60</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10774701</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Radical resection benefits patients suffering pancreatic ductal adenocarcinoma with liver oligometastases.</pubmed_title><pmcid>PMC10774701</pmcid><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Kong Q</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Teng F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Radical resection benefits patients suffering pancreatic ductal adenocarcinoma with liver oligometastases.</name><description>&lt;h4>Purpose&lt;/h4>Whether patients suffering liver oligometastases from pancreatic ductal adenocarcinoma (LOPDA) should undergo surgical treatment remains controversial.&lt;h4>Methods&lt;/h4>PubMed and Embase databases were systematically reviewed until 2023 June. Survival data were collected from the Kaplan-Meier curves. Safety and survival were evaluated using primary outcomes such as 1-year, 3-year, and 5-year survival rates, and 30-day mortality and morbidity. A subgroup meta-analysis was conducted to compare survival rates post-synchronous resection and resection post-neoadjuvant chemotherapy in LOPDA.&lt;h4>Results&lt;/h4>Our analysis of 15 studies involving 1,818 patients (surgical group, 648 and nonsurgical group, 1,170) indicates that radical hepatectomy for LOPDA notably improved 1-year (odds </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan</publication><modification>2025-04-04T13:58:48.313Z</modification><creation>2025-04-04T13:58:48.313Z</creation></dates><accession>S-EPMC10774701</accession><cross_references><pubmed>38205094</pubmed><doi>10.4174/astr.2024.106.1.51</doi></cross_references></HashMap>